Benzinga | Feb 17, 2021 12:09PM EST

Jefferies Maintains Buy on Horizon Therapeutics, Raises Price Target to $120

Jefferies analyst David Steinberg maintains Horizon Therapeutics (NASDAQ:HZNP) with a Buy and raises the price target from $103 to $120.